Background {#Sec1}
==========

Rectal cancer has been defined as a cancerous lesion located within 12 cm of the anal verge \[[@CR1]\]. At present, the main treatment for locally advanced rectal cancer is chemoradiotherapy plus total mesorectal excision (TME). Although it is debatable whether preoperative chemoradiotherapy improves long-term survival \[[@CR2]--[@CR4]\], randomized clinical trials have shown better local control, lower toxicity, and higher compliance if preoperative chemoradiotherapy is administered rather than postoperative conventionally fractionated chemoradiotherapy \[[@CR5], [@CR6]\]. Thus, the current "gold standard" of treatment recommended by both the National Comprehensive Cancer Network (NCCN) \[[@CR7]\] and the European Society for Medical Oncology (ESMO) \[[@CR8]\] for locally advanced rectal cancers with invading through the muscularis propria into the pericolorectal tissues (cT3), penetrating to the surface of the visceral peritoneum (cT4a), invading or being adherent to other organs or structures (cT4b), or lymph nodal metastasis on imaging (cN1-2) is preoperative radiotherapy plus 5-fluorouracil (5-FU)-based chemotherapy.

Is adjuvant chemotherapy needed after curative surgery for rectal cancer patients who have received neoadjuvant chemoradiotherapy? The NCCN recommended postoperative chemotherapy for all patients undergoing preoperative chemoradiotherapy regardless of the pathological stage \[[@CR7]\]. The ESMO guidelines state that "similar to the situation in colon cancer Stages III (and "high-risk" Stage II), adjuvant chemotherapy can be provided, even if the scientific support for sufficient effect is less" \[[@CR8]\]. However, several studies questioned the use of adjuvant chemotherapy in patients with rectal cancer who underwent neoadjuvant chemoradiotherapy and curative surgery, especially in patients without pathological lymph node metastasis (ypN0) \[[@CR2], [@CR9]--[@CR14]\]. Results from all these studies showed that adding postoperative adjuvant chemotherapy did not significantly improve disease-free survival (DFS) or overall survival (OS) in patients who have already received neoadjuvant chemoradiotherapy. On the other hand, a unique randomized clinical trial suggested that good-prognosis patients (ypT0-2) benefit from postoperative chemotherapy \[[@CR15]\]. Furthermore, it was not reported whether adding postoperative 5-FU-based chemotherapy could improve the survival of patients with pathological lymph node metastasis (ypN1-2). Hence, for patients who have received neoadjuvant therapy, the role of postoperative chemotherapy is still controversial.

Although lack of data from rigorous randomized clinical trials confirmed the effectiveness, oxaliplatin has been used in rectal cancer for several years based on the extrapolated data in colon cancer. Similarly, the role of postoperative oxaliplatin in patients with rectal cancer who have already received neoadjuvant chemoradiotherapy is still not yet defined. To the best of our knowledge, only two ongoing randomized clinical trials presented preliminary results, though contradictory, on this issue \[[@CR16], [@CR17]\].

The aim of the current study was to investigate whether postoperative 5-FU-based chemotherapy or 5-FU plus oxaliplatin provides a benefit for patients with resected rectal cancer who have already received 5-FU-based neoadjuvant chemoradiotherapy.

Methods {#Sec2}
=======

Data source {#Sec3}
-----------

The data from the Surveillance, Epidemiology, and End Results (SEER)--Medicare-linked database were examined. The approval and subsequent access to the data for this study were granted by the National Cancer Institute (NCI) and Information Management Services (IMS), Inc. following submission of a formal data request outlining the research objectives. Also, this study was approved by the Institutional Review Board of the first hospital of China Medical University.

The SEER cancer registries include information on patient demographics, tumor characteristics, first course of treatment, and survival of patients who were newly diagnosed with cancer. SEER regions included approximately 26% of the US population \[[@CR18]\]. Medicare is the primary health insurer for 97% of the US population aged ≥65 years \[[@CR19]\]. The details of the database were presented elsewhere \[[@CR20]\].

Patient selection {#Sec4}
-----------------

All Medicare-enrolled patients aged ≥66 years that were diagnosed with primary adenocarcinoma of the rectum from 1992 to 2008 were included in the study (SEER cancer site codes: 19.9 and 20.9; SEER histology codes: 8000--8152, 8154--8231, 8243--8245, 8250--8576, 8940--8950, and 8980--8981). Those who underwent primary tumor resection with likely curative intent within 180 days of diagnosis were selected, excluding presumably palliative operations. Data of all patients who received preoperative (from diagnosis of rectal cancer to operation) radiotherapy plus 5-FU or capecitabine, which was the regimen recommended by the NCCN, were included. Regarding the postoperative chemotherapy, the no-chemo group included patients with no record for chemotherapy within 120 days of surgery. The oxaliplatin group included patients with any record of oxaliplatin within 30 days of their first chemotherapy dose. The 5-FU group comprised all other patients, including those who received 5-FU or capecitabine. The Health Care Financing Administration Common Procedure Coding System or National Drug Code for drugs were presented in Additional file [1](#MOESM1){ref-type="media"}.

Patients were excluded from this study if they (1) received other chemotherapy regimen preoperatively or postoperatively; (2) had prior non-rectal cancer; (3) had incomplete pathological stage entries or diagnostic data; (4) died during the immediate postoperative period (within 30 days); (5) were diagnosed with another malignancy 1 year after the date of rectal cancer diagnosis; (6) had membership in a Medicare-sponsored health maintenance organization or lack of enrollment in Medicare Parts A and B from 12 months preceding diagnosis through 9 months after diagnosis; (7) had complete pathologic response because it was unable to identify accurately in the SEER-Medicare database; and (8) had ypStage 0 (Tis N0 M0), because of too small sample size.

Variables {#Sec5}
---------

Age at diagnosis, year of diagnosis, sex, race, marital status, rural/urban county of residence, census tract-level median household income, and level of education (percentage of people aged \>25 years and \<12 years of education) were obtained from the SEER patient entitlement and diagnosis summary file. For risk adjustment, Centers for Medicare and Medicaid Services Hierarchical Condition Categories (HCC) based on outpatient and inpatient diagnoses from the 12 months before rectal cancer diagnosis were used. The resulting score can be interpreted as a patient's predicted level of "future health care need" relative to the average Medicare beneficiary (HCC = 1.0) \[[@CR21]\].

Patients were staged according to the seventh edition of the Union for International Cancer Control (UICC) tumor-node-metastasis (TNM) staging system \[[@CR22]\]. Postoperative pathological stage (ypTNM) was used. The preoperative clinical stage was not available in the SEER-Medicare. Other covariates included were tumor grade, histological type, preoperative intestinal obstruction, preoperative intestinal perforation, postoperative radiotherapy, and the number of lymph nodes examined.

Statistical analysis {#Sec6}
--------------------

In the univariable analysis, the cancer-specific (CSS) was analyzed by Kaplan-Meier survival curves, and comparisons were made by the log-rank test stratified by the ypTNM stage.

In clinical practice, significant differences exist between patients who are and are not treated with chemotherapy, particularly with regard to age and comorbidities. Because treatment effect estimates are likely confounded by factors related to treatment selection, a propensity score (PS)-matched analysis was performed to compare the effect of treatment on survival among patients of similar risk profiles as assessed by measured known confounders \[[@CR23], [@CR24]\]. For this analysis, logistic regression models were built for each stage to estimate each patient's probability of receiving 5-FU or oxaliplatin, conditional on covariates. Later two PSs were generated: one estimated the likelihood of 5-FU receipt and the other estimated the likelihood of oxaliplatin receipt in chemotherapy-treated patients. For each comparison, patients exposed to treatment (5-FU and oxaliplatin) were matched with patients with the same PS from the unexposed treatment group. Patients for whom there was no match were excluded. In this manner, a PS-matched cohort balanced across treatment groups for measured confounders was generated. The CSS was then compared in these PS-matched cohorts using the log-rank test stratified by the ypTNM stage.

As the sample size was moderate, a Cox proportional hazards model was also used in the adjusted analysis. The covariates included all variables that were identified to be significantly related to survival in the univariable analysis and the tests were made stratified by the ypTNM stage.

All statistical analyses and graphics were performed by the lead author using SAS 9.3 (SAS Institute, Cary, NC, USA), STATA 12.0 software (STATA, College Station, TX, USA), and PASW Statistics 18.0 software (SPSS, Inc., Somers, NY, USA). For all analyses, *P* \< 0.05 was considered to indicate a significant result.

Results {#Sec7}
=======

Patient demographics {#Sec8}
--------------------

A total of 1535 patients with resected rectal cancer who received neoadjuvant chemoradiotherapy regimen recommended by the NCCN were included (Table [1](#Tab1){ref-type="table"}). Details of race, marital status, median household income, level of education, histologic type, and intestinal perforation were not presented in Table [1](#Tab1){ref-type="table"}, because the number of patients in some subgroups was too small and the SEER-Medicare rules require that cell sizes less than eleven in a table must be suppressed.Table 1**Clinicopathologic features of patients with different chemotherapy regimens**No-chemo5-FUOxaliplatinGender  Male448321131  Female32421992Age at diagnosis, years  66-70201184105  71-7523417570  \>7533718148Residence location  Big Metro383261127  Metro or Urban30319977  Less Urban or Rural868019Year of diagnosis  1992-199617100  1997-20001321150  2001-200429625126  2005-2008327164197Histologic grade  Well593514  Moderate519360146  Poor/Undifferentiated1168737  Unknown785826ypT category  ypT1-226114650  ypT3446367160  ypT4652713ypN category  ypN0609339134  ypN1a798534  ypN1b425926  ypN2a203616  ypN2b222113ypTNM stage  ypTNM I23311336  ypTNM II37622698  ypTNM III16320189Intestinal obstruction  No677484201  Yes955622HCC risk score  1st quartile21014356  2nd quartile15713145  3rd quartile18915267  4th quartile21611455Number of examined lymph node  ≥12265200106  \<12507340117Postoperative radiotherapy  No676455208  Yes968515*Abbreviation*s: *HCC* Hierarchical Condition Categories, *No-chemo* without postoperative chemotherapy, *5-FU* 5-fluorouracil.

CSS without chemotherapy or with 5-FU {#Sec9}
-------------------------------------

The unmatched 5-year CSS rates for the patients in the no-chemo group were 90.6%, 78.8%, and 49.5% as compared with 90.9%, 84.0%, and 59.0% for the 5-FU group in ypStage I (T1-2 N0 M0), II (T3-4 N0 M0), and III (Any T N1-2 M0), respectively (Figure [1](#Fig1){ref-type="fig"}). There was no significant difference in survival between two groups in ypStage I (*P* = 0.961) and ypStage II (*P* = 0.109). The prognosis of patients in the no-chemo group was significantly worse than the 5-FU group in ypStage III (*P* = 0.024).Figure 1**Kaplan-Meier comparison of cancer-specific survival among patients who received different postoperative treatment stratified by pathologic stage. A.** ypStage I; **B.** ypStage II; **C.** ypStage III.

The variables that were significantly related to the patients' probability of receiving 5-FU were presented in Additional file [2](#MOESM2){ref-type="media"}. The PS-matched cohorts were generated using these variables. The CSS was then compared in these PS-matched cohorts. There were still no significant differences in survival between the two groups in ypStage I (*P* = 0.884) and ypStage II (*P* = 0.345), but for patients in ypStage III the prognosis of the no-chemo group was significantly worse than the 5-FU group (*P* = 0.009; Figure [2](#Fig2){ref-type="fig"}).Figure 2**After PS-matched, Kaplan-Meier comparison of cancer-specific survival between patients in the no-chemo group and in the 5-FU group stratified by pathologic stage. A.** ypStage I; **B.** ypStage II; **C.** ypStage III.

A Cox proportional hazards model was also used for comparison of survival between the two groups. The covariates included all variables that were identified to be significantly related to survival (Additional file [3](#MOESM3){ref-type="media"}). The results were consistent with that of the PS-matched analysis, and in ypStage III, the patients in the no-chemo group was significantly worse than the 5-FU group (hazard ratio = 1.547, 95% CI = 1.101-2.173, *P* = 0.012; Table [2](#Tab2){ref-type="table"}).Table 2**Cox proportional hazards model stratified by ypTNM stage**HR95%CIPStage I  Chemotherapy regimens   5-FU1   No-chemo1.0210.459-2.2730.960   Oxaliplatin1.0020.215-4.6700.998Stage II  ypT category   ypT31   ypT4a1.1870.291-4.8410.811   ypT4b1.8781.058-3.3340.031  Postoperative radiotherapy   No1   Yes1.8701.159-3.0180.010  Histologic type   Adenocarcinoma1   Mucinous carcinoma1.8771.138-3.0940.014   Signet-ring cell carcinoma8.0782.351-27.7480.001  Chemotherapy regimens   5-FU1   No-chemo1.3930.903-2.1480.134   Oxaliplatin0.9260.438-1.9560.840Stage III  ypT category   ypT11.1500.491-2.6920.747   ypT20.7590.436-1.3210.329   ypT31   ypT4a0.6910.244-1.9590.487   ypT4b1.5920.934-2.7130.088  ypN category   ypN1a1   ypN1b1.2330.825-1.8440.306   ypN2a1.4680.905-2.3810.119   ypN2b2.0981.310-3.3570.002  Residence location   Big Metro1   Metro or Urban1.1470.822-1.6000.419   Less Urban or Rural0.4870.257-0.9230.027  Histologic type   Adenocarcinoma1   Mucinous carcinoma1.4660.993-2.1630.054   Signet-ring cell carcinoma1.2200.459-3.2390.690  Histologic grade   Well0.7160.229-2.2390.565   Moderate1   Poor1.6500.753-3.6190.211   Undifferentiated2.8170.891-8.9100.078   Unknown1.0370.496-2.1710.922  Chemotherapy regimens   5-FU1   No-chemo1.5471.101-2.1730.012   Oxaliplatin0.6260.372-1.0540.078*Abbreviations*: *No-chemo* without postoperative chemotherapy, *5-FU* 5-fluorouracil, *CI* Confidential intervals.

CSS with or without oxaliplatin {#Sec10}
-------------------------------

The unmatched 5-year CSS rates for the patients in the oxaliplatin group were 91.1%, 87.9%, and 73.7% as compared with 90.9%, 84.0%, and 59.0% for the 5-FU group in ypStage I, II, and III, respectively (Figure [1](#Fig1){ref-type="fig"}). There were no significant differences in survival between the two groups in all stages (*P* ≥; 0.05).

The variables that significantly related to the patients' probability of receiving 5-FU plus oxaliplatin compared with 5-FU alone were presented in Additional file [2](#MOESM2){ref-type="media"}. The PS-matched cohorts were generated using these variables. The CSS was then compared in these PS-matched cohorts. There were still no significant differences in survival between the two groups in all stages (*P* \> 0.05; Figure [3](#Fig3){ref-type="fig"}).Figure 3**After PS-matched, Kaplan-Meier comparison of cancer-specific survival between patients in the 5-FU group and in the oxaliplatin group stratified by pathologic stage. A**. ypStage I; **B**. ypStage II; **C**. ypStage III.

A Cox proportional hazards model was also used for comparison of survival between the two groups. The covariates included all variables which were identified to be significantly related to survival (Additional file [3](#MOESM3){ref-type="media"}). The results showed that there were still no significant differences in survival between the two groups in all stages (Table [2](#Tab2){ref-type="table"}).

Discussion {#Sec11}
==========

Preoperative chemoradiotherapy is the standard treatment for locally advanced rectal cancer. However, there is no general agreement about whether patients who have already received neoadjuvant chemoradiotherapy need further postoperative chemotherapy based on 5-FU. Janjan \[[@CR25]\] proposed that there was significant improvement in CSS in response to preoperative chemoradiotherapy and the administration of adjuvant chemotherapy. Collette \[[@CR15]\] analyzed a subset of data from the European Organization for Research and Treatment of Cancer (EORTC) Trial 22921, which revealed that the postoperative 5-FU-based chemotherapy prolonged survival in ypT0-2, but not in ypT3-4, patients. Hypothetically, distal micrometastasis may be cleared by chemotherapeutic drugs more effectively in patients who were good in response (in low ypStage) to preoperative chemoradiotherapy.

However, Das \[[@CR26]\] proposed that postoperative chemotherapy may be of greater benefit for patients in a higher ypStage such as ypStage III (ypN1-2), and lower ypStage subgroups should receive a relatively conservative therapeutic regimen. Subsequently, a study by Huh \[[@CR11]\] revealed that postoperative adjuvant chemotherapy for patients in ypT0-2 N0 classification after preoperative chemoradiation and curative surgery did not significantly improve the survival, which was consistent with the suggestion of Das \[[@CR26]\], but these results contradictory to that of Collette \[[@CR15]\]. Later the results of the study by Govindarajan \[[@CR9]\] confirmed that there was no significant difference in the 5-year DFS between patients, in ypT0-2 N0 and ypT3-4 N0 classifications, who did and did not receive adjuvant treatment. In addition, both Fietkau \[[@CR10]\] and Kiran \[[@CR12]\] proposed that adding postoperative chemotherapy did not significantly improve the survival of patients in ypN0 classification. More recently, Bosset \[[@CR14]\] completed the EORTC Trial 22921 and proposed that postoperative 5-FU-based chemotherapy after preoperative radiotherapy (with or without chemotherapy) did not affect DFS or OS. The result was confirmed in both ypT0-2 and ypT3-4 classifications; however, this analysis was not stratified on the basis of ypN classification.

Although the conclusions of the aforementioned studies were different, a consensus may be arrived at based on the postoperative pathologic stage of the patient in determining the need for adjuvant chemotherapy. Simultaneously, several studies proposed that the risk of distant metastases is directly proportional to the postoperative pathologic stage \[[@CR9], [@CR27]--[@CR29]\], and Quah \[[@CR28]\] found that the outcome was most accurately estimated by the postoperative pathologic stage. Nevertheless, the NCCN recommended postoperative chemotherapy for all patients undergoing preoperative chemoradiotherapy regardless of the results of the surgical pathology tests \[[@CR7]\].

Considering the importance of ypTNM stage in determining the need for adjuvant chemotherapy, all tests were made stratified by ypTNM stage. We compared the prognosis among patients in no-chemo, 5-FU, and oxaliplatin group in the unmatched univariable survival analysis. We found that postoperative 5-FU-based chemotherapy did not prolong the CSS in ypStage I (ypT1-2 N0) (Figure [1](#Fig1){ref-type="fig"}A) and ypStage II (ypT3-4 N0) (Figure [1](#Fig1){ref-type="fig"}B), which was similar to the study by Govindarajan \[[@CR9]\]. On the contrary, adding postoperative 5-FU-based chemotherapy significantly improved survival of patients in ypStage III (ypN1-2) (Figure [1](#Fig1){ref-type="fig"}C). To the best of our knowledge, the outcome of postoperative 5-FU-based chemotherapy in ypStage III patients was never reported previously, although researchers stressed the need for a randomized clinical trial \[[@CR30], [@CR31]\]. To confirm our results, both the PS-matched analysis and the Cox proportional hazards model were used to make adjusted analysis, and the results were in accordance with the univariable survival analysis (Figure [2](#Fig2){ref-type="fig"}, Table [2](#Tab2){ref-type="table"}).

Adding oxaliplatin to fluoropyrimidines in the adjuvant setting improved the OS in colon cancer compared with FU and leucovorin regimens \[[@CR32]\]. According to the NCCN guidelines, for patients with resected rectal cancer who have already received 5-FU-based neoadjuvant chemoradiotherapy, 5-FU/leucovorin/oxaliplatin (FOLFOX) was an optional regimen for postoperative chemotherapy. Several ongoing randomized clinical trials in rectal cancer focused on improving 5-FU-based chemotherapy through the addition of oxaliplatin preoperatively, postoperatively, or both \[[@CR16], [@CR17], [@CR33]--[@CR35]\]. Two study groups presented preliminary results. Hong \[[@CR17]\] proposed that postoperative FOLFOX significantly improved the 2-year DFS relative to postoperative 5-FU-based chemotherapy for rectal cancer patients in ypStage II or III after 5-FU-based neoadjuvant chemoradiotherapy followed by TME. On the contrary, Nimeiri \[[@CR16]\] discovered that there was no difference in the OS between patients who received 5-FU alone or FOLFOX as postoperative chemotherapy. In the current study, no significant differences were found in the survival between the two groups (5-FU vs. oxaliplatin) of patients with resected rectal cancer who have already received 5-FU-based neoadjuvant chemoradiotherapy (Figures [1](#Fig1){ref-type="fig"} and [3](#Fig3){ref-type="fig"}; Table [2](#Tab2){ref-type="table"}). Although this result need to be confirmed by further clinical trials, we argue that, for patients who received neoadjuvant chemoradiotherapy, adding oxaliplatin to fluoropyrimidines in the postoperative chemotherapy require serious consideration at present.

The current study has some limitations. First, as it was a retrospective exploratory study, the potential for confounding based on patient selection could not be eliminated. Both traditional Cox proportional hazards model and PS-matched techniques were used to account for known relevant confounders. Second, only patients aged ≥66 years at the time of diagnosis were included in this study, which may limit the applicability of the findings to younger patients with rectal cancer. Third, the role of several known prognostic features such as tumor regression grade, preoperative carcinoembryonic antigen, microsatellite instability, perineural invasion, and lymphovascular invasion could not be investigated, as these characteristics were not available within the SEER-Medicare database. Patients with pCR were excluded from analysis because the pCR status was not well supported by the SEER-medicare database. Fourth, this study retrospectively examined the use of chemotherapy as identified through the Medicare claims data using a "one-claim" algorithm \[[@CR36], [@CR37]\]. This created a heterogeneous population in which some patients received a substandard duration of therapy. However, O\'Connor \[[@CR38]\] proposed that the "none versus any" approach used to assign treatment status provided a window into the effectiveness of chemotherapy in real-world practice, in which an individual's likelihood of completing the treatment course is not known at the outset of the study. Finally, the preoperative clinical stage as well as pathologic response to neoadjuvant therapy was not supported by the SEER-Medicare database. Both the preoperative clinical stage and pathologic response were related to outcome; however, Quah \[[@CR28]\] found that the outcome was most accurately estimated by the postoperative pathologic stage and the clinical stage adds no predictive value to the prognosis. In addition, the 100% accuracy of clinical staging was untenable even in the best of centers \[[@CR39]\]. Based on this, the decision of postoperative chemotherapy could be regarded mainly as based on postoperative pathologic stage.

Conclusions {#Sec12}
===========

It is concluded that, for patients with resected rectal cancer who have already received 5-FU-based neoadjuvant chemoradiotherapy, postoperative 5-FU-based chemotherapy prolongs the CSS of groups in ypStage III. Adding oxaliplatin to fluoropyrimidines in the postoperative chemotherapy did not improve the CSS for patients who received neoadjuvant chemoradiotherapy.
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